海辰药业(300584) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.18% compared to ¥150,605,102.60 in the same period last year[5] - Net profit attributable to shareholders was ¥12,213,813.89, down 3.23% from ¥12,620,961.53 year-on-year[5] - The company's basic and diluted earnings per share were both ¥0.1018, a decrease of 3.23% compared to ¥0.1052 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥117,201,090.18, a decrease of 22.2% compared to ¥150,605,102.60 in Q1 2022[21] - Net profit for Q1 2023 was ¥12,213,813.89, slightly down from ¥12,448,499.59 in the same period last year, a decrease of 1.9%[22] Cash Flow - The net cash flow from operating activities improved significantly to ¥29,506,108.77, a 173.51% increase from a negative cash flow of -¥40,136,476.98 in the previous year[5] - Operating cash flow for Q1 2023 was ¥29,506,108.77, a significant improvement from a negative cash flow of ¥40,136,476.98 in Q1 2022[24] - The net cash flow from financing activities was ¥21,493,951.38, a 235.30% increase compared to -¥15,886,571.19 in the same period last year[9] - The net cash flow from investment activities was -53,605,687.16 CNY, compared to a net cash inflow of 23,247,822.60 CNY in the previous period[25] - Cash inflow from financing activities was 49,000,000.00 CNY, while cash outflow was 27,506,048.62 CNY, resulting in a net cash flow of 21,493,951.38 CNY[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,333,752,341.08, reflecting a 3.08% increase from ¥1,293,945,410.29 at the end of the previous year[5] - The total assets of the company as of March 31, 2023, were approximately 1.33 billion RMB, an increase from 1.29 billion RMB at the beginning of the year[18] - The company’s total liabilities increased to approximately 337.83 million RMB from 317.05 million RMB at the beginning of the year[18] - The total liabilities increased to ¥370,907,991.94 from ¥343,379,013.86, an increase of 8.1%[22] Equity - The total equity attributable to shareholders increased by 1.29% to ¥962,844,349.14 from ¥950,566,396.43 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company rose to ¥962,844,349.14 from ¥950,566,396.43, an increase of 1.3%[22] Research and Development - Research and development expenses decreased by 37.09% to ¥3,013,143.82 from ¥4,789,264.33 year-on-year[9] - Research and development expenses were ¥3,013,143.82, down 37.5% from ¥4,789,264.33 in the previous year[21] Sales Performance - Sales of the product "Injectable Lantidilol 50mg" reached 340,600 units, with a sales amount of 47.78 million RMB, representing an 88% increase in volume and 89% increase in sales amount year-over-year[15] - Sales of "Rivaroxaban Tablets 15mg*7" decreased by 10% in both volume and sales amount, totaling 217,300 boxes and 13.36 million RMB[15] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[11] Other Financial Metrics - The net profit excluding non-recurring gains and losses increased by 4.08% year-over-year to 12.57 million RMB[14] - Accounts receivable decreased from 185.38 million RMB at the beginning of the year to 167.74 million RMB[17] - The company’s cash and cash equivalents at the end of Q1 2023 were approximately 92.47 million RMB, down from 95.07 million RMB at the beginning of the year[17] - The total cash and cash equivalents at the end of the period amounted to 92,465,697.80 CNY, down from 113,795,568.27 CNY at the beginning of the period[25] - The company reported a decrease in cash and cash equivalents of -2,602,425.67 CNY for the quarter[25] Audit Information - The company did not conduct an audit for the first quarter report[26]